Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

UCB Announces Positive Phase 3 Results for Rozanolixizumab in Generalized Myasthenia Gravis

AmericanPharmaceuticalReviewDecember 13, 2021

Tag: Rozanolixizumab , Myasthenia Gravis , UCB

PharmaSources Customer Service